InflaRx Outlined Multiple Data Analyses Of The Phase 3 Study For Vilobelimab In Pyoderma Gangrenosum, Which Was Terminated Earlier In 2025 After An Independent Data Monitoring Committee Recommended To Stop The Trial Early Due To Futility
Benzinga Newsdesk 10 months ago
BiotechHealth CareGeneral
While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc
- While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect
- InflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in collaboration with a partner